BioXcel Therapeutics to Present at 29th Annual Oppenheimer Healthcare Conference
March 13 2019 - 04:01PM
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced,
that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI,
will present at the 29th Annual Oppenheimer Healthcare Conference
being held March 19-20, 2019 in New York, NY. BTI is a clinical
stage biopharmaceutical development company utilizing novel
artificial intelligence approaches to identify the next wave of
medicines across neuroscience and immuno-oncology.
Details of
the presentations are below: |
Event: |
29th Annual Oppenheimer
Healthcare Conference |
Date: |
March
19, 2019 |
Time: |
1:35 PM ET |
A live webcast of the presentation will be accessible through
the Investors section of the Company's website at
www.bioxceltherapeutics.com. Following the conference, the webcast
will be archived on the BioXcel Therapeutics, Inc. website for 30
days.
In addition to his presentation, Dr. Mehta will be hosting
1-on-1 investor meetings at the conference. Investors attending the
conference who are interested in meeting with BTI management should
contact their Oppenheimer representatives.
About BioXcel Therapeutics, Inc.:BioXcel
Therapeutics, Inc. is a clinical stage biopharmaceutical company
focused on drug development that utilizes novel artificial
intelligence to identify the next wave of medicines across
neuroscience and immuno-oncology. BTI's drug re-innovation approach
leverages existing approved drugs and/or clinically validated
product candidates together with big data and proprietary machine
learning algorithms to identify new therapeutic indices. BTI's two
most advanced clinical development programs are BXCL501, a
sublingual thin film formulation designed for acute treatment of
agitation resulting from neurological and psychiatric disorders,
and BXCL701, an immuno-oncology agent designed for treatment of a
rare form of prostate cancer and for treatment of pancreatic
cancer. For more information, please visit
www.bioxceltherapeutics.com.
Contact Information:BioXcel TherapeuticsThe
Ruth GroupLee Roth/ Janhavi Mohite646-536-7012/
7026
lroth@theruthgroup.com/ jmohite@theruthgroup.com
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Mar 2023 to Mar 2024